Angstrom Biotech
Angstrom Biotech is a Private Indian company incorporated in 2000 and based in Gujarat, India. Angstrom Biotech operates in Pharmaceuticals & Chemicals (NIC 24119) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Angstrom Biotech - Manufacturer of diagnostic kit and reagents for research purpose.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Angstrom Biotech.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +27d | filed |
| MGT-7 | FY2024-25 | 26 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +39d | filed |
| MGT-7 | FY2023-24 | 20 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Angstrom Biotech.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 208727752 | HDFC Bank Ltd(Bank) | ₹13.09 Cr | 27 Jan 2021 | Satisfied |
| 426465437 | Kotak Mahindra Bank Ltd(Bank) | ₹23.71 Cr | 12 Mar 2019 | Open |
| 183394519 | ICICI Bank Ltd(Bank) | ₹17.63 Cr | 27 Jan 2022 | Open |
| 826918828 | ICICI Bank Ltd(Bank) | ₹24.59 Cr | 19 Sep 2023 | Satisfied |
| 978289328 | Kotak Mahindra Bank Ltd(Bank) | ₹20.66 Cr | 12 Mar 2022 | Open |
Charge IDs, lenders & amounts for Angstrom Biotech.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹48.24 Cr | ₹-1.29 Cr | ₹40.48 Cr | ₹72.03 Cr | 67 |
| FY2023-24 | ₹44.61 Cr | ₹-1.86 Cr | ₹17.40 Cr | ₹53.39 Cr | 365 |
| FY2022-23 | ₹42.61 Cr | ₹-90.34 L | ₹24.10 Cr | ₹47.52 Cr | 300 |
| FY2021-22 | ₹26.37 Cr | ₹-83.04 L | ₹19.21 Cr | ₹27.71 Cr | 57 |
Audited financials & ratios for Angstrom Biotech.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹48.24 Cr | ₹44.61 Cr | ₹42.61 Cr | ₹26.37 Cr |
| Other income | ₹1.37 Cr | ₹47.00 L | ₹1.19 Cr | ₹18.90 L |
| Total income | ₹49.61 Cr | ₹45.08 Cr | ₹43.79 Cr | ₹26.56 Cr |
| Total expenses | ₹51.26 Cr | ₹47.47 Cr | ₹44.95 Cr | ₹27.62 Cr |
| Profit before tax | ₹-1.68 Cr | ₹-2.42 Cr | ₹-1.17 Cr | ₹-1.08 Cr |
| Profit / (Loss) after tax | ₹-1.29 Cr | ₹-1.86 Cr | ₹-90.34 L | ₹-83.04 L |
| Balance sheet | ||||
| Equity / Net worth | ₹40.48 Cr | ₹17.40 Cr | ₹24.10 Cr | ₹19.21 Cr |
| Borrowings | ₹10.67 Cr | ₹8.55 Cr | ₹10.98 Cr | ₹3.33 Cr |
| Current liabilities | ₹10.24 Cr | ₹12.07 Cr | ₹12.31 Cr | ₹3.67 Cr |
| Total liabilities | ₹31.56 Cr | ₹36.00 Cr | ₹23.42 Cr | ₹8.50 Cr |
| Current assets | ₹38.19 Cr | ₹28.46 Cr | ₹20.84 Cr | ₹13.05 Cr |
| Cash & equivalents | ₹6.38 Cr | ₹8.52 Cr | ₹3.71 Cr | ₹4.66 Cr |
| Total assets | ₹72.03 Cr | ₹53.39 Cr | ₹47.52 Cr | ₹27.71 Cr |
| Employees | 67 | 365 | 300 | 57 |
Audited financials & ratios for Angstrom Biotech.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹48.24 Cr | -1.0% | +16.0% | +6.5% |
| Profit after Tax | ₹-1.29 Cr | +29.2% | +19.0% | +21.6% |
| Net Worth | ₹40.48 Cr | -2.3% | +1.5% | +15.2% |
| Employees | 67 | +33.9% | +20.2% | +11.3% |
Audited financials & ratios for Angstrom Biotech.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹48.24 Cr | ₹-1.29 Cr | -2.68% | +38.35% | -3.19% | -1.79% | 0.26 | ₹72.00 L |
| FY2023-24 | ₹44.61 Cr | ₹-1.86 Cr | -4.18% | -12.64% | -10.71% | -3.49% | 0.49 | ₹12.22 L |
| FY2022-23 | ₹42.61 Cr | ₹-90.34 L | -2.12% | +14.21% | -3.75% | -1.90% | 0.46 | ₹14.20 L |
| FY2021-22 | ₹26.37 Cr | ₹-83.04 L | -3.15% | +36.44% | -4.32% | -3.00% | 0.17 | ₹46.26 L |
Audited financials & ratios for Angstrom Biotech.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 99,68,793 | 79.52% |
| Institutional Investors | 1 | 4,86,570 | 3.88% |
| Public & Others | 63 | 20,80,157 | 16.59% |
Promoter, institutional & public holding for Angstrom Biotech.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
28 peersExternal data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.